However, the clinical application of exosomal gene markers still faces challenges: on the one hand, the heterogeneity of peripheral blood exosomes may lead to fluctuations in marker abundance; on the other hand, the physiological functions of S100A11 in normal tissues require that targeted therapies must be equipped with precise tumor-specific delivery systems. Here, S100A11 is linked to neoplasm.